1 of 1
Story summary
- The OCEANIC-STROKE trial found that adding asundexian to antiplatelet therapy reduces ischemic stroke risk in acute noncardioembolic stroke or high-risk TIA without increasing bleeding.
- Over two years, ischemic stroke occurred in 6.2% of asundexian patients versus 8.4% with placebo.
- The trial enrolled 12,237 patients across 37 countries and showed consistent benefits across subgroups.
- Experts say asundexian could transform stroke prevention, but patient selection is crucial, especially for atrial fibrillation.
